Tag Archives: Pravastatin

Statins for the Treatment of Vascular Dementia or Alzheimer’s Disease (Cochrane Database)

Posted on July 26, 2014 by Dementia and Elderly Care News

Summary This Cochrane systematic review assesses the clinical efficacy and safety of statins for the treatment of Alzheimer’s Disease and vascular dementia. No studies exist yet assessing role of statins in treatment of vascular dementia. Analysis of four studies concerning … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights | Tagged ADAS-Cog: Alzheimer’s Disease Assessment Scale - Cognitive Subscale, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Alzheimer’s Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Alzheimer’s Disease Functional Assessment and Change Scale (ADFACS), Atorvastatin, Belfast Health and Social Care Trust, Centre for Public Health: Queen's University Belfast, Cholesterol Reduction, Clinical Global Impression of Change (CGIC), Cochrane Database, Cochrane Dementia and Cognitive Improvement Group (CDCIG), Craigavon Area Hospital, Department of Geriatric Medicine: Belfast Health and Social Care Trust, Fluvastatin, Hypercholesterolaemia, Kingshill Research Centre: Victoria Hospital (Swindon), Lovastatin, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Pravastatin, Queen's University Belfast, Rosuvastatin, Simvastatin, Statin Therapy, Statins, Statins for the Treatment of Alzheimer’s Disease, Statins for the Treatment of Vascular Dementia, University of Oxford, Use of Statins, VaD: Vascular Dementia, Vascular Dementia | Leave a comment

Statins: Effective, Affordable and Acceptable Risk-Benefit Profile (BBC News / NICE / BMJ / BMC Medicine)

Posted on July 19, 2014 by Dementia and Elderly Care News

Summary According to latest guidelines from the National Institute for Health and Care Excellence (NICE), four out of ten adults in England, Wales and Northern Ireland will be eligible for statins; even though they are at relatively low risk of … Continue reading →

Posted in Acute Hospitals, BBC News, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, National, NHS, NICE Guidelines, Northern Ireland, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Scotland, Standards, Statistics, Stroke, Systematic Reviews, UK, Universal Interest, Wales | Tagged Adherence to Statin Therapy, Adverse Effects, Alcohol Consumption, Atorvastatin, BBC Health News, BMC Medicine, BMJ, British Medical Association's General Practitioner Committee, British Medical Journal (BMJ), Cancer, Cardioprotective Diet, Cardiovascular Disease, Cardiovascular Risk, Cataracts, Cholesterol, Cholesterol Levels, Cholesterol-Lowering Drugs, Cholesterol-Lowering Medications, Chronic Obstructive Pulmonary Disease, Cognition, Cognitive Decline, Cognitive Impairment, Combined Interventions (Diet and Physical Activity), Concerns Over Statins Use, COPD, Costs of Statins (Declining), County Hospital (Hereford), CVD Risk Assessment, CVD: Cardiovascular Disease, Department of Geriatric Medicine: County Hospital (Hereford), Diabetes, Drug Side-Effects, Erectile Dysfunction, Evidence-Based Medicine, Eyes and Vision, Fatigue, Fluvastatin, Grouping of Statins (Three Intensity Categories), Harvard Medical School, Healthy Lifestyles, Hepatotoxicity, Informed Choice, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, JUPITER Study, Kidney Disorders, Lifestyle Modifications for Primary and Secondary Prevention of CVD, Lifestyle Risk Factors, Lifestyle Weight Management, Lipid Lowering and Onset of Renal Disease (LORD) Study, Lipid Modification, Lipophilic Statins, Liver Disorders, Liver Toxicity, London School of Hygiene and Tropical Medicine, Low Density Lipoprotein Cholesterol (LDL-C), Mass Prescription, MCI: Mild Cognitive Impairment, Memory Lapses, Memory Loss, Memory Problems, Mild Cognitive Impairment (MCI), Misinformation About Statins (Historical), Modifiable Risk Factors, Muscle Toxicity, Musculo-Skeletal Disorders, Myopathy, National Institute for Health and Care Excellence (NICE), Neurological Disorders, Neuronal Cell Membranes, NHS Choices Health A-Z Information on Statins, NHS Choices: Healthy Cooking, NHS Choices: Healthy Diet, NHS Choices: Healthy Eating, NHS Choices: Physical Activity, NHS Health Checks Programme, NICE Clinical Guideline CG181, NICE Clinical Guideline CG67, Non-Cardiovascular Effects Associated With Statins, Non-Cardiovascular Harms of Statins, Non-Cardiovascular Side-Effects of Statins, Off-Label Use, Over-Medicalisation (Speculative Concept), Overdiagnosis (Speculative Concept), Overtreatment (Speculative Concept), Pancreatitis, Patient Choice, Patient-Doctor Discussion, Physical Activity, Physical Activity Prescriptions, Physical Activity Programmes, Potential Harms Associated With Statins, Pravastatin, Preventative Mass Prescription, Prospective Study of Pravastatin in the Elderly (PROSPER) Trial, QRISK2 Assessment Tool, QRISK2 Calculator, Renal Disorders, Respiratory Disorders, Rhabdomyolysis, Risk Factors, Risk Factors of Stroke, Rosuvastatin, Scandinavian Simvastatin Survival Study, Simvastatin, Smoking Cessation, Smoking Cessation Services, Statin Induced Myopathy, Statins, Statins for Stroke Prevention in Older Patients, Statins: Contraindicated in Pregnancy, Statins: Few Contraindications, Statins: Risk-Benefit Profile, Stroke Prevention in Older Patients, Stroke Risk Factor Modification, Unintended Effects of Statins, Urological Disorders, Use of Drugs Outside Their Licensed Indications, Use of Statins, Venous Thromboembolism, Weight Management | Leave a comment

Exposure to Statins in Early Old Age May Lower Risk of Alzheimer’s Disease

Posted on February 3, 2011 by Dementia and Elderly Care News

[This abstract first appeared in: Dementia: the Latest Evidence Newsletter RWHT Volume 1 Issue 7 February 2011]. Abstract This US prospective cohort study looked into whether statins (simvastatin, lovastatin, pravastatin and atorvastatin) reduce the risk of Alzheimer’s Disease (AD), and investigated the influence … Continue reading →

Posted in For Researchers (mostly), Universal Interest | Tagged Alzheimer's Gene (APOE4 Gene), Alzheimer’s Disease, APOE4 Gene, Apolipoprotein E (APOE) e4 Allele, Atorvastatin, Lovastatin, Pravastatin, Simvastatin, Statins | Leave a comment

Tag Archives: Pravastatin

Statins: Effective, Affordable and Acceptable Risk-Benefit Profile (BBC News / NICE / BMJ / BMC Medicine)

Exposure to Statins in Early Old Age May Lower Risk of Alzheimer’s Disease

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites